Dividend stocks for your July 2024 watchlist.
Despite markets reaching new heights recently, many defensive stocks with reliable and consistent demand are still experiencing their own market dip. They have pulled back as investors repositioned into the artificial intelligence (AI) trend.
24/7 Insights Wounded blue chip stocks can offer huge total return potential.
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday.
AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices, high dividend yields, and potential for market-beating returns. W.P. Carey yields 6.3% and offers growth potential through European property acquisitions, while Bristol Myers Squibb gives a 5.6% yield and has growth prospects driven by a strong drug pipeline.
Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs.
Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, why I sold them, my barbell strategy, and how much cash I am holding in my investment portfolios.
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this period.
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.